1 Cowell, C. F. et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol7, 859-869, doi:10.1016/j.molonc.2013.07.005 (2013).
2 Veronesi, U. et al. Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer. 347, 1227-1232, doi:10.1056/NEJMoa020989 (2002).
3 Litière, S. et al. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. The Lancet Oncology13, 412-419, doi:10.1016/S1470-2045(12)70042-6 (2012).
4 Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. The Lancet Oncology16, 266-273, doi:https://doi.org/10.1016/S1470-2045(14)71221-5 (2015).
5 Morrow, M. et al. Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma. CA: A Cancer Journal for Clinicians52, 277-300, doi:10.3322/canjclin.52.5.277 (2002).
6 McCormick, B. et al. RTOG 9804: A Prospective Randomized Trial for Good-Risk Ductal Carcinoma In Situ Comparing Radiotherapy With Observation. Journal of Clinical Oncology33, 709-715, doi:10.1200/jco.2014.57.9029 (2015).
7 van Maaren, M. C. et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. The Lancet Oncology17, 1158-1170, doi:10.1016/s1470-2045(16)30067-5 (2016).
8 Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet366, 2087-2106, doi:10.1016/s0140-6736(05)67887-7 (2005).
9 Moertel, C. G., Dockerty, M. B. & Baggenstoss, A. H. Multiple primary malignant neoplasms. II. Tumors of different tissues or organs. Cancer14, 231-237, doi:10.1002/1097-0142(196103/04)14:2<231::aid-cncr2820140203>3.0.co;2-2 (1961).
10 Silverman, B. G., Lipshitz, I. & Keinan-Boker, L. Second Primary Cancers After Primary Breast Cancer Diagnosis in Israeli Women, 1992 to 2006. J Glob Oncol3, 135-142, doi:10.1200/jgo.2016.003699 (2017).
11 Yi, M. et al. Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy. Ann Surg Oncol20, 1514-1521, doi:10.1245/s10434-012-2774-8 (2013).
12 Li, Z., Wang, K., Shi, Y., Zhang, X. & Wen, J. Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study. Int J Cancer146, 352-362, doi:10.1002/ijc.32259 (2020).
13 Goldstraw, P. et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol11, 39-51, doi:10.1016/j.jtho.2015.09.009 (2016).
14 Austin, P. C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharmaceutical Statistics10, 150-161, doi:10.1002/pst.433 (2011).
15 Austin, P. C. & Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statistics in medicine34, 3661-3679, doi:10.1002/sim.6607 (2015).
16 An, J. H. et al. A Possible Association Between Thyroid Cancer and Breast Cancer. Thyroid25, 1330-1338, doi:10.1089/thy.2014.0561 (2015).
17 Withrow, D. R., Morton, L. M., Curtis, R. E., Schonfeld, S. J. & Berrington de Gonzalez, A. Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers. Breast Cancer Res Treat166, 299-306, doi:10.1007/s10549-017-4410-6 (2017).
18 Innos, K. & Horn-Ross, P. L. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment111, 531-540, doi:10.1007/s10549-007-9807-1 (2008).
19 Kushner, C. J., Hwang, W. T., Wang, S., Solin, L. J. & Vapiwala, N. Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Res Treat170, 45-53, doi:10.1007/s10549-018-4729-7 (2018).
20 Shaitelman, S. F. et al. Rates of Second Malignancies After Definitive Local Treatment for Ductal Carcinoma In Situ of the Breast. International Journal of Radiation Oncology*Biology*Physics81, 1244-1251, doi:10.1016/j.ijrobp.2010.07.2005 (2011).
21 Mannu, G. S. et al. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ369, m1570, doi:10.1136/bmj.m1570 (2020).
22 Parveen, B. et al. Risk of Second Primary Thyroid Cancer after Radiotherapy for a Childhood Cancer in a Large Cohort Study: An Update from the Childhood Cancer Survivor Study. Radiation Research174, 741-752, doi:10.1667/RR2240.1 (2010).
23 Inskip, P. D. Pelvic radiotherapy, sex hormones, and breast cancer. Cancer Causes Control5, 471-478, doi:10.1007/bf01694761 (1994).
24 Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S. & Formenti, S. C. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol4, 325, doi:10.3389/fonc.2014.00325 (2014).
25 Suzuki, R. et al. Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. J Radiat Res61, 440-446, doi:10.1093/jrr/rraa005 (2020).
26 Blok, E. J. et al. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). JNCI: Journal of the National Cancer Institute110, 40-48, doi:10.1093/jnci/djx134 (2018).
27 Giannakeas, V., Sopik, V. & Narod, S. A. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open1, e181100, doi:10.1001/jamanetworkopen.2018.1100 (2018).